Tonghua Dongbao's aspart insulin approved for Dominican Republic market

Tonghua Dongbao Pharmaceutical Co., Ltd. announced its aspart insulin injection received a drug registration certificate from the Ministry of Public Health and Social Welfare of the Dominican Republic. The approved product is an aspart insulin injection, available as a pre-filled pen, indicated for diabetes.

This approval allows Tonghua Dongbao to sell aspart insulin injection in the Dominican Republic. The country has a growing demand for diabetes treatment, with 1.2037 million people aged 20-79 suffering from the condition in 2024, representing a prevalence of 16.6%.

This registration is expected to enhance the company's international product portfolio, boost its brand image, expand international operations, and strengthen its competitiveness in emerging markets. While preliminary production preparations are underway, actual sales performance will depend on market demand, policy changes, and competition.